Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.

PURPOSE The synthetic retinoid fenretinide administered for 5 years for prevention of second breast cancer showed no difference after a median of 8 years, but a possible reduction in premenopausal women. We conducted a long-term analysis in a subgroup of women who were regularly followed up in a single center. PATIENTS AND METHODS We analyzed data after a median follow-up of 14.6 years (IQ range, 12.3-16.3 years) from 1739 women aged 30-70 (872 in the fenretinide arm and 867 in the observation arm), representing 60% of the initial cohort of 2867 women. The main efficacy endpoint was second primary breast cancer (contralateral or ipsilateral). RESULTS The number of second breast cancers was 168 in the fenretinide arm and 190 in the control arm (hazard ratio = 0.83, 95% CI, 0.67-1.03). There were 83 events in the fenretinide arm and 126 in the observation arm in premenopausal women (HR = 0.62, 95% CI, 0.46-0.83), and 85 and 64 events in postmenopausal women (HR = 1.23, 95% CI, 0.63-2.40). The younger were the women, the greater was the risk reduction associated with fenretinide, which attained 50% in women aged 40 years or younger and disappeared after age 55 (P-age*treatment interaction = 0.023). There was no difference in cancers in other organs, distant metastases or survival. CONCLUSIONS Fenretinide induces a significant risk reduction of second breast cancer in premenopausal women, which is remarkable at younger ages, and persists several years after treatment cessation. Since adverse events are limited, a trial in young women at high-risk is warranted.

[1]  M. Sporn,et al.  N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. , 1979, Cancer research.

[2]  D. Mccormick,et al.  Influence of delayed administration of retinyl acetate on mammary carcinogenesis. , 1982, Cancer research.

[3]  B. Hankey,et al.  A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy. , 1983, Journal of the National Cancer Institute.

[4]  R. Moon,et al.  Inhibition of mammary tumorigenesis in nulliparous C3H mice by chronic feeding of the synthetic retinoid, N-(4-hydroxyphenyl)-retinamide. , 1983, Carcinogenesis.

[5]  J. Krayer,et al.  Teratogenicity of N-(4-hydroxyphenyl)-all-trans-retinamide in rats and rabbits. , 1988, Teratogenesis, carcinogenesis, and mutagenesis.

[6]  R. Simon,et al.  Flexible regression models with cubic splines. , 1989, Statistics in medicine.

[7]  M. Pizzichetta,et al.  Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. , 1989, Cancer research.

[8]  R. Mehta,et al.  Distribution of fenretinide in the mammary gland of breast cancer patients. , 1991, European journal of cancer.

[9]  M. Sporn,et al.  Carcinogenesis and cancer: different perspectives on the same disease. , 1991, Cancer research.

[10]  S. Ward,et al.  Comparative teratogenicity of nine retinoids in the rat. , 1992, International journal of experimental pathology.

[11]  M. Clerici,et al.  Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Catsafados,et al.  The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. , 1993, Cancer research.

[13]  U. Veronesi,et al.  Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. , 1994, Cancer research.

[14]  D. Coradini,et al.  Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[15]  R. Lotan.  Retinoids and apoptosis: implications for cancer chemoprevention and therapy. , 1995, Journal of the National Cancer Institute.

[16]  B. Asselain,et al.  Contralateral breast cancer: annual incidence and risk parameters. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Mariani,et al.  Chemoprevention Trial of Contralateral Breast Cancer with Fenretinide. Rationale, Design, Methodology, Organization, Data Management, Statistics and Accrual , 1997, Tumori.

[18]  U. Veronesi,et al.  Human transplacental passage of the retinoid fenretinide (4HPR) , 1998, European journal of cancer.

[19]  B. O’Malley,et al.  Hormone-induced refractoriness to mammary carcinogenesis in Wistar-Furth rats. , 1998, Carcinogenesis.

[20]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[21]  James Dignam,et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial , 1999, The Lancet.

[22]  S. Lippman,et al.  Advances in the development of retinoids as chemopreventive agents. , 2000, The Journal of nutrition.

[23]  B. O’Malley,et al.  p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Mariani,et al.  Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. , 2001, Journal of the National Cancer Institute.

[25]  L. Mariani,et al.  Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. Mariani,et al.  Effect of fenretinide on ovarian carcinoma occurrence. , 2002, Gynecologic oncology.

[27]  S. Lippman,et al.  Cancer prevention science and practice. , 2002, Cancer research.

[28]  V. Steele,et al.  Effects of Body Weight Gain Reduction Resulting From Chemopreventive Agent Treatment on Mammary Gland Morphology , 2002, Nutrition and cancer.

[29]  L. Mariani,et al.  Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  A. Sabichi,et al.  Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  M. Cazzaniga,et al.  Breast Cancer Prevention Trials Using Retinoids , 2004, Journal of Mammary Gland Biology and Neoplasia.

[32]  A. Tari,et al.  How retinoids regulate breast cancer cell proliferation and apoptosis , 2004, Cellular and Molecular Life Sciences CMLS.

[33]  V. Steele,et al.  N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. , 2005, Carcinogenesis.

[34]  D. J. Jerry,et al.  Sensitivity to DNA Damage Is a Common Component of Hormone-Based Strategies for Protection of the Mammary Gland , 2005, Molecular Cancer Research.

[35]  M. Cazzaniga,et al.  Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.